InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board

TSX:IN
OTCQB:IMLFF

VANCOUVER, May 1, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today the addition of Dr. Vikramaditya G. Yadav to its Scientific Advisory Board. Dr. Yadav is an Assistant Professor in the Department of Chemical & Biological Engineering and School of Biomedical Engineering at the University of British Columbia (UBC), and currently serves as the Chair of the Biotechnology Division of the Chemical Institute of Canada. He has been recognized by Medicine Maker journal as one of the 100 most influential people in drug development and manufacturing.

"We are delighted to welcome Dr. Yadav as a formal member of the Company's Scientific Advisory Board," said Dr. Sazzad Hossain, Chief Scientific Officer of InMed. "Dr. Yadav has been instrumental in advancing InMed's proprietary cannabinoid biosynthesis program. Our novel approach, which utilizes genetically engineered bacteria for the production of drugs, is currently being scaled up and optimized to manufacture therapeutically relevant cannabinoids at high yields in a commercial setting. Dr. Yadav and his team's work on strain engineering and optimization have been the building blocks for InMed's current and continued success, as well as the source of several submitted and planned patents."

Dr. Yadav received his doctoral degree in chemical engineering from the Massachusetts Institute of Technology. His graduate work focused on enzyme and microbial metabolic engineering for the synthesis of pharmaceuticals. He later conducted post-doctoral research on biophysics and biological thermodynamics at Harvard University. He joined UBC, Canada's pre-eminent center for biotechnology research, in the summer of 2014 and has since established a world-leading, industry- connected research group that works on wide-ranging topics such as metagenomics, plant chemistry, tissue engineering, drug discovery and pharmaceutical manufacturing. Dr. Yadav received his bachelor's degree in chemical engineering from the University of Waterloo.

InMed is also developing novel formulations for drug candidates under Dr. Yadav's leadership. This pipeline of projects includes a proprietary, first-of-its-kind nanoparticle-laden hydrogel for ocular drug delivery. "We look forward to continued collaborations with Dr. Yadav and his team, and welcome his on-going strategic scientific guidance as InMed continues to explore novel systems for cannabinoid manufacturing and delivery," stated Dr. Hossain.

Dr. Yadav noted, "My research group has been working closely with InMed Pharmaceuticals over the past three years. Our collaboration has been very fruitful and we have been able to conduct pioneering research on clinically relevant topics. I am pleased to formalize my commitment to the R&D activities by joining the Scientific Advisory Board. I look forward to achieving greater heights with the Company in the years ahead."

About InMed:
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking  statements"  (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: Dr. Yadav joining InMed's Scientific Advisory Board; scaling up and optimizing InMed's proprietary cannabinoid biosynthesis program to manufacture therapeutically relevant cannabinoids at high yields in a commercial setting; planned patents; developing novel formulations for drug candidates; and the expected fundamental value drivers of the Company.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Dr. Yadav's continued availability; continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for InMed's products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: Dr. Yadav may become unwilling or unable to serve on InMed's Scientific Advisory Board; submitted and planned patents may not be approved; economic or market conditions may worsen; and InMed's proprietary bioinformatics platform, biosynthesis manufacturing process and drug development programs may not deliver the expected level of results nor become the fundamental value drivers of the Company. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.

Investor Contact: InMed Pharmaceuticals Inc., Josh Blacher, Chief Business Officer, T: [phone], E: [email protected]

Related Links

www.inmedpharma.com